Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$2.26
Day's Change
-0.2067 (-8.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.31
Day's Low
2.16
Volume
(Heavy Day)

Today's volume of 168,941 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.

168,941

SHAREHOLDER ALERT: U.S. Bancorp (USB) Officers and Directors Under Investigation for Alleged Breaches of Fiduciary Duty and False Statements

2:42 pm ET January 4, 2023 (PR Newswire) Print

Schubert Jonckheer & Kolbe LLP is investigating potential claims on behalf of shareholders of U.S. Bancorp (NYSE: USB) related to undisclosed risks about the company's consumer products and services.

U.S. Bancorp is a Delaware company headquartered in Minneapolis, Minnesota. U.S. Bancorp provides a full range of financial services, including lending and depository services, cash management, capital markets, and trust and investment management services.On July 28, 2022, the Consumer Financial Protection Bureau (CFPB) issued a Consent Order against US Bancorp's banking subsidiary, U.S. Bank National Association ("U.S. Bank"). According to the Consent Order, from 2010 to 2020, U.S. Bank prioritized revenue generation over regulatory compliance. The Company's sales policies incentivized employees to open deposit accounts and credit lines on behalf of customers without their knowledge and consent. One such policy was an incentive compensation program, which offered financial rewards to employees for selling high-revenue-generating products and services. This employee misconduct continued unchecked for years because the Company failed to implement adequate controls to address its operational and compliance risks. The Company failed to disclose these risks to shareholders and investors.

The Schubert Firm is investigating potential breaches of fiduciary duty by U.S. Bancorp's officers and directors in connection with these allegations.

If you own stock in U.S. Bancorp and wish to obtain additional information about your legal rights, please contact ustoday or visit our website at https://www.classactionlawyers.com/usb

About Schubert Jonckheer & Kolbe LLP

Schubert Jonckheer & Kolberepresents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco, and with the help of co-counsel, litigates cases nationwide.

https://c212.net/c/img/favicon.png?sn=DC77345&sd=2023-01-04

View original content:https://www.prnewswire.com/news-releases/shareholder-alert-us-bancorp-usb-officers-and-directors-under-investigation-for-alleged-breaches-of-fiduciary-duty-and-false-statements-301713780.html

SOURCE Schubert Jonckheer & Kolbe LLP

https://rt.newswire.ca/rt.gif?NewsItemId=DC77345&Transmission_Id=202301041442PR_NEWS_USPR_____DC77345&DateId=20230104

comtex tracking

COMTEX_422148233/1005/2023-01-04T14:42:56

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.